drugset / Trial / NCT05545319

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319

Phase 2 Withdrawn Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19

Timeline

Start
2022-12-13
Primary completion
2023-09-21
Completion
2024-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nirmatrelvir Small molecule 150 mg Oral
Subject Nirmatrelvir Small molecule 300 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral